Vera Therapeutics (NASDAQ: VERA) experienced a notable increase in its stock price, closing 13% higher on Wednesday, following a positive analyst note. Cantor Fitzgerald’s Pete Stavropoulos maintained an overweight rating and set a price target of $100 per share, which is over three times the current share price. This endorsement significantly contributed to the stock’s rise. Vera continues to attract investor attention in the biotech sector.
Loading PerspectiveSplit analysis...
